echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > JGH: Analysis of risk factors for recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with direct-acting antiviral drugs

    JGH: Analysis of risk factors for recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with direct-acting antiviral drugs

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Patients with chronic hepatitis C may develop life-threatening complications, including hepatocellular carcinoma (HCC) and liver failure, mainly due to progressive liver fibrosis


     


     


    Figure: Time chart of SVR recurrence

     



    Original source:

    Eiichi Ogawa.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.